Santiago Thibaud

11PUBLICATIONS
58CO-AUTHORS
Haematological tumoursMedical mycologyCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Nov 05, 2025
Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression.

Junia Vieira Dos Santos, David T Melnekoff, Adolfo Aleman

|Aug 13, 2025
Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy.

Zachary M Avigan, Jerrel Catlett, Saoirse Bodnar

|Nov 15, 2024
MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma.

Lucia Y Chen, Santiago Thibaud, Saoirse Bodnar

|Oct 09, 2024
Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival.

Zachary M Avigan, Saoirse Bodnar, Darren Pan

|Sep 16, 2024
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes.

Santiago Thibaud, Ryan L Subaran, Scott Newman

|May 22, 2024
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma.

Mateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz

Pageof 2

Frequent Collaborators

9 joint publications

Hearn Jay Cho

8 joint publications

Joshua Richter

8 joint publications

Sundar Jagannath

5 joint publications

Tarek H Mouhieddine